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Abstract
Background:  Epidemiologic and laboratory investigations suggest that nonsteroidal anti-
inflammatory drugs (NSAIDs) have chemopreventive effects against breast cancer due to their
activity against cyclooxygenase-2 (COX-2), the rate-limiting enzyme of the prostaglandin cascade.
Methods: We conducted a case control study of breast cancer designed to compare effects of
selective and non-selective COX-2 inhibitors. A total of 323 incident breast cancer patients were
ascertained from the James Cancer Hospital, Columbus, Ohio, during 2003–2004 and compared
with 649 cancer free controls matched to the cases at a 2:1 ratio on age, race, and county of
residence. Data on the past and current use of prescription and over the counter medications and
breast cancer risk factors were ascertained using a standardized risk factor questionnaire. Effects
of COX-2 inhibiting agents were quantified by calculating odds ratios (OR) and 95% confidence
intervals.
Results: Results showed significant risk reductions for selective COX-2 inhibitors as a group (OR
= 0.29, 95% CI = 0.14–0.59), regular aspirin (OR = 0.49, 95% CI = 0.26–0.94), and ibuprofen or
naproxen (0.36, 95% CI = 0.18–0.72). Acetaminophen, a compound with negligible COX-2 activity
and low dose aspirin (81 mg) produced no significant change in the risk of breast cancer.
Conclusion: Selective COX-2 inhibitors (celecoxib and rofecoxib) were only recently approved
for use in 1999, and rofecoxib (Vioxx) was withdrawn from the marketplace in 2004. Nevertheless,
even in the short window of exposure to these compounds, the selective COX-2 inhibitors
produced a significant (71%) reduction in the risk of breast cancer, underscoring their strong
potential for breast cancer chemoprevention.
Background
The recent recall of rofecoxib (Vioxx) from the market-
place due its alleged association with increased risk for
cardiovascular disease has severely compromised further
testing of all selective cyclooxygenase-2 (COX-2) inhibi-
tors in the chemoprevention and therapy of cancer.
Despite compelling evidence that COX-2 inhibitors have
powerful anti-cancer effects, several clinical trials designed
to evaluate these compounds in the chemoprevention and
therapy of neoplasms have been discontinued or sus-
pended [1,2].
Both the magnitude and the direction of effect of selective
COX-2 blockers on the risk of cardiovascular disease is the
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subject of controversy. Risk increases have been observed
with use of rofecoxib and celecoxib in clinical trials that
were designed to evaluate their potential for treating
arthritis or reducing colonic polyp recurrence [3-5],
whereas risk decreases  have been observed in observa-
tional studies that were designed to evaluate effects of
these same compounds on cardiovascular diseases [6-8].
Still other investigations suggest that COX-2 inhibitors
have no effect on the risk of myocardial infarction and
related cardiovascular events [9,10].
Among American women, breast cancer is the most fre-
quently diagnosed malignancy and second leading cause
of cancer death [11]. Despite intensive efforts aimed pri-
marily at early detection and therapy, the mortality rates
of breast cancer have remained virtually constant for sev-
eral decades. Innovative research efforts must therefore be
redirected towards chemoprevention of the early stages of
carcinogenesis. Among twenty published epidemiologic
studies that focused on the association between intake of
nonsteroidal anti-inflammatory drugs (NSAIDs) and the
risk of human breast cancer, 13 reported statistically sig-
nificant risk reductions. Meta-analysis of these data sug-
gests that regular NSAID intake significantly reduces the
risk of breast cancer [12].
Two selective COX-2 inhibitors, celecoxib (Celebrex) and
rofecoxib (Vioxx), were approved for the treatment of
arthritis by the United States Food and Drug Administra-
tion (FDA) in 1999. Until the recall of Vioxx in Septem-
ber, 2004, these two compounds plus other selective
COX-2 inhibitors valdecoxib (Bextra) and meloxicam
(Mobic) were widely utilized in the United States for pain
relief and treatment of osteoarthritis and rheumatoid
arthritis. The time period between approval of Celebrex to
the recall of Vioxx provides an approximate six-year win-
dow for evaluation of exposure to such compounds by a
case control approach. The current case control study was
designed to test the chemopreventive value of selective
COX-2 blockade against human breast cancer.
Methods
We studied 323 cases of invasive breast cancer with histo-
logical verification based upon review of the pathology
records, and 649 group-matched controls with no per-
sonal history of cancer and no current breast disease based
on screening mammography. Cases were sequentially
ascertained for interview at the time of their diagnosis dur-
ing 2003 through September, 2004 at The Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute
(CHRI), Columbus, Ohio. There were no refusals to par-
ticipate among cases. The controls were ascertained from
the mammography service of the cancer hospital during
the same time period and frequency matched to the cases
at a rate of 2:1 by five-year age interval, race, and place
(county) of residence. Controls were sequentially ascer-
tained for each matching category resulting in a stratified
random sample. Among women eligible for participation,
95% completed the questionnaire.
Critical information on exposure to NSAIDs and other
factors were obtained utilizing a standardized risk factor
questionnaire. The questionnaires were administered in
person by trained medical personnel prior to definitive
surgery or treatment for the cases and at the time of
screening mammography for controls. The data variables
collected consisted of demographic characteristics, height,
weight, menstrual and pregnancy history, family history
of breast and ovarian cancer, comprehensive information
on cigarette smoking, alcohol intake, pre-existing medical
Table 1: Characteristics of breast cancer cases and controls.
Characteristic a Cases 
(N = 323)
Controls 
(N = 649)
Age (yrs)
<50 21% 22 %
50–65 55 56
>65 24 22
Mean (SEM) 54.2 (0.7) 53.3 (0.4)
Race
Caucasian 91 % 89 %
All Other 91 1
Education
< 12 yrs 12 % 12 %
12 yrs 53 55
> 12 yrs 31 33
Parity
Nulliparous 6 % 4 %
First Pregnancy <30 yrs 83 89
First Pregnancy >30 yrs 11 7 (p < 0.05)
Family History
Positive 29 % 16 %
Negative 71 84 (p < 0.01)
Body Mass
BMI < 22 23 % 21 %
BMI 22–28 35 39
BMI > 28 42 40
Mean (SEM) 27.5 (0.9) 27.1 (0.7)
Menopausal Status
Premenopausal 41 % 47 %
Postmenopausal 59 53 (p < 0.05)
Postmenopausal ERT 38 31 (p < 0.05)
Smoking
Never smoker 45 % 40 %
Ex-smoker 38 40
Current smoker 27 20 (p < 0.02)
Alcohol Intake
None 47 % 45 %
1–2 drinks per week 36 35
> 2 drinks per week 17 20
a Family History: either breast or ovarian cancer among first or 
second degree female relatives; ERT = Estrogen Replacement Therapy 
for two or more years; Body Mass Index = weight (kg)/ht2(m).BMC Cancer 2006, 6:27 http://www.biomedcentral.com/1471-2407/6/27
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conditions (arthritis, chronic headache, cardiovascular
conditions including hypertension, angina, ischemic
attacks, stroke, and myocardial infarction, lung disease,
and diabetes mellitus), and medication history including
over the counter (OTC) and prescription NSAIDs, and
exogenous hormones. Regarding selective COX-2 inhibi-
tors and other NSAIDs, the use pattern (frequency, dose,
and duration), and the type, (celecoxib, valdecoxib,
rofecoxib, meloxicam, aspirin, ibuprofen, naproxen,
indomethacin) were recorded. Data on the related analge-
sic, acetaminophen were collected for comparison with
selective COX-2 inhibitors and other NSAIDs.
Case-control differences in means and frequencies were
checked for statistical significance by t-tests and chi square
tests, respectively. Effects of the selective COX-2 inhibitors
as a group were quantified by estimating odds ratios and
their 95% confidence intervals. Odds ratios were adjusted
for age and classical breast cancer risk factors (parity, fam-
ily history, body mass, menopausal status, chronic smok-
ing, and regular alcohol intake) by logistic regression
analysis [13,14]. Adjusted estimates were obtained for
specific types of compounds, e.g., over the counter
NSAIDs, selective COX-2 inhibitors, and acetaminophen.
Results
Pertinent characteristics of the cases and controls are given
in Table 1. The cases exhibited higher frequencies of nul-
liparity, family history of breast or ovarian cancer, estro-
gen replacement therapy in postmenopausal subjects, and
chronic cigarette smoking. As expected, cases and controls
had similar distributions of age, race, and education.
Table 2 shows the comparative frequencies of the medica-
tions under study with odds ratios and 95% confidence
intervals. Age-adjusted and multivariate-adjusted esti-
mates are presented. A significant reduction in the risk of
breast cancer was observed for daily intake of selective
COX-2 inhibitors for two years or more (OR = 0.29, 95%
CI = 0.14–0.59). Significant risk reductions were also
observed for the intake of two or more pills per week of
regular aspirin (OR = 0.49, 95% CI = 0.26–0.95), and ibu-
profen or naproxen (OR = 0.37, 95% CI = 0.18–0.72).
Neither acetaminophen nor baby aspirin (81 mg) had any
effect on the relative risk of breast cancer.
Table 3: Odds ratios for breast cancer by dose, frequency, and duration of exposure to celecoxib, rofecoxib, aspirin, and ibuprofen.
Compounda Dose Frequency of Use Multivariate ORb (95% CI)
Celecoxib 200 mg Daily 0.17 (0.03–0.83)
Rofecoxib 25 mg Daily 0.36 (0.14–0.91)
Aspirin 325 mg 2–3 weekly 1.02 (0.30–3.57)
>3 weekly 0.39 (0.22–0.72)
trend (p < 0.05)
Ibuprofen 200 mg 2–3 weekly 0.59 (0.21–1.67)
>3 weekly 0.28 (0.13–0.61)
trend (p < 0.01)
a Minimum duration of exposure: 2 years for celecoxib or rofecoxib, 5 years for aspirin or ibuprofen.
b Multivariate odds ratios are adjusted for continuous variables (age and body mass) and categorical variables (parity, menopausal status, family 
history, smoking, and alcohol intake).
Table 2: Odds ratios with 95% confidence intervals for breast cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and over the 
counter nonsteroidal anti-inflammatory drugs (OTC NSAIDS).
Compound Number of Cases Number of Controls Age Adjusted OR 
(95% CI)
Multivariate ORd 
(95% CI)
None/Infrequent Usea 262 453 1.00 1.00
COX-2 Inhibitorsb 10 52 0.31 (0.16–0.64) 0.29 (0.14–0.59)
OTC NSAIDsc
Aspirin 15 40 0.51 (0.27–0.98) 0.49 (0.26–0.94)
Ibuprofen/Naproxen 11 52 0.37 (0.18–0.71) 0.37 (0.18–0.72)
Acetaminophen 8 16 0.92 (0.39–2.20) 1.02 (0.39–2.20)
Baby Aspirin 17 36 0.82 (0.40–1.40) 0.77 (0.42–1.41)
a No use of any NSAID or analgesic or infrequent use of no more than one pill per week for less than one year;
b COX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, and meloxicam used daily for two years or more.
c Over the counter (OTC) NSAIDs/analgesics used at least two times per week for two years or more.
d Multivariate odds ratios are adjusted for continuous variables (age and body mass) and categorical variables (parity, menopausal status, family 
history, smoking, and alcohol intake).BMC Cancer 2006, 6:27 http://www.biomedcentral.com/1471-2407/6/27
Page 4 of 5
(page number not for citation purposes)
Table 3 presents risk estimates for individual selective
COX-2 inhibitors (celecoxib and rofecoxib) plus dose-
response data for aspirin and ibuprofen. Daily use of
either 200 mg celecoxib or 25 mg rofecoxib for at least two
years produced significant risk reductions (83% and 64%
respectively). The trend data for OTC compounds suggests
that 325 mg aspirin or 200 mg ibuprofen produced signif-
icant risk reductions when taken at least every other day
for 5 or more years.
Discussion
This is the first observation of a significant risk reduction
in human breast cancer due to intake of selective COX-2
inhibitors. Standard daily dosages of celecoxib (200 mg)
or rofecoxib (25 mg) taken for two or more years were
associated with a 71% reduction in breast cancer risk.
Comparator NSAIDs with non-selective COX-2 activity
(325 mg aspirin, 200 mg ibuprofen or 250 mg naproxen)
also produced significant risk reductions, although their
observed effects were not as strong as selective com-
pounds. In contrast, neither acetaminophen nor 81 mg
(baby) aspirin changed the risk of breast cancer.
In general, NSAIDs inhibit cyclooyxgenase which is the
key rate-limiting enzyme of prostaglandin biosynthesis
[15-17]. Molecular studies show that the inducible COX-
2 gene is over-expressed in human breast cancer and that
COX-2 genetic expression in cancer cells is correlated with
mutagenesis, mitogenesis, angiogenesis, and deregulation
of apoptosis [18-20]. Over the counter NSAIDs have con-
sistently shown antitumor effects in animal models of car-
cinogenesis [21], and in recent studies, striking antitumor
effects of the specific COX-2 inhibitor, celecoxib, have
been observed against breast cancer [22]. In breast cancer
cells, COX-2 over-expression is also associated with CYP-
19 P-450arom genetic expression and local estrogen biosyn-
thesis [23-25]. The current study coupled with existing
preclinical and molecular evidence suggest that aberrant
induction of COX-2 and up-regulation of the prostaglan-
din cascade play a significant role in mammary carcino-
genesis, and that blockade of this process has strong
potential for intervention.
Enthusiasm for the use of selective COX-2 blocking agents
in the chemoprevention of breast cancer and other malig-
nancies has been tempered by reports of adverse effects on
the cardiovascular system leading to the recall of popular
anti-arthritic compounds, rofecoxib (Vioxx) and val-
decoxib (Bextra). However, such studies involved supra-
therapeutic dosages given over long periods of time with-
out consideration of body size or individual differences in
metabolism [26].
Conclusion
We observed a significant reduction in the risk of human
breast cancer due to intake of selective COX-2 inhibitors.
Chemopreventive effects against breast cancer were asso-
ciated with recommended daily doses of celecoxib
(median dose = 200 mg) or rofecoxib (median dose = 25
mg) for an average duration of 3.6 years. Notably, selec-
tive COX-2 inhibitors (celecoxib and rofecoxib) were only
recently approved for use in 1999, and rofecoxib (Vioxx)
was withdrawn from the marketplace in 2004. Neverthe-
less, even in the short window of exposure to these com-
pounds, the selective COX-2 inhibitors produced a
significant (71%) reduction in the risk of breast cancer,
underscoring their strong potential for breast cancer che-
moprevention.
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